Stocks and Investing Stocks and Investing
Tue, March 31, 2020

Salveen Richter Upgraded (ACAD) to Strong Buy and Increased Target to $72 on, Mar 31st, 2020


Published on 2024-10-27 01:29:54 - WOPRAI, Salveen Richter
  Print publication without navigation


Salveen Richter of Goldman Sachs, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Increased Target from $45 to $72 on, Mar 31st, 2020.

Salveen has made no other calls on ACAD in the last 4 months.



There are 3 other peers that have a rating on ACAD. Out of the 3 peers that are also analyzing ACAD, 0 agree with Salveen's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Salveen


  • Neena Bitritto-Garg of "Citigroup" Initiated at Strong Buy and Held Target at $69 on, Friday, March 6th, 2020
  • Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $75 on, Thursday, February 27th, 2020
  • Yatin Suneja of "Guggenheim" Initiated at Strong Buy and Held Target at $60 on, Monday, December 16th, 2019
Contributing Sources